McEwan, P., Morgan, A. R., Boyce, R., Bergenheim, K., Gause‐Nilsson, I. A., Bhatt, D. L., . . . Wilding, J. P. (2021). The cost‐effectiveness of dapagliflozin in treating high‐risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE‐TIMI 58 trial. Diabetes Obes Metab.
Dyfyniad Arddull ChicagoMcEwan, Phil, et al. "The Cost‐effectiveness of Dapagliflozin in Treating High‐risk Patients With Type 2 Diabetes Mellitus: An Economic Evaluation Using Data From the DECLARE‐TIMI 58 Trial." Diabetes Obes Metab 2021.
Dyfyniad MLAMcEwan, Phil, et al. "The Cost‐effectiveness of Dapagliflozin in Treating High‐risk Patients With Type 2 Diabetes Mellitus: An Economic Evaluation Using Data From the DECLARE‐TIMI 58 Trial." Diabetes Obes Metab 2021.